Conservative management of upper tract transitional cell carcinoma

Markian R. Iwaszko, Amy Krambeck

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Aim: Our aim was to review the current literature describing the endoscopic management of upper tract transitional cell carcinoma (TCC). Materials and Methods: Review of published, peer-reviewed articles relating the primary ureteroscopic or percutaneous management of upper tract TCC was performed using the MEDLINE database. Results: Historically, the gold-standard management for upper tract TCC consists of nephroureterectomy with excision of a bladder cuff. The employment of endoscopic management with these neoplasms was initially instituted in individuals with imperative indications, including bilateral disease, solitary kidney, and/or renal insufficiency. For individuals treated with ureteroscopy, recurrence rates range from 30 to 71% and cancer-specific survival rates from 50 to 93%. Results are dependent primarily on tumor grade and stage. In individuals with low-stage, low-grade tumors treated percutaneously, recurrence rates, and cancer-specific survival rates are 18-33% and 94-100%, respectively. Adjuvant therapy has been employed with thiotepa, mitomycin, and BCG, but none have been able to demonstrate a statistically significant difference in recurrence or cancer-specific survival rates. Conclusions: Endoscopic management is a safe and effective treatment alternative to nephroureterectomy in the management of upper tract TCC. Survival outcomes are comparable, but renal preservation therapy offers the advantage of reduced morbidity, complications, and the potential for better quality of life. Recurrence and disease progression are not uncommon and underscore the need for strict tumor surveillance.

Original languageEnglish (US)
Pages (from-to)159-163
Number of pages5
JournalIndian Journal of Urology
Volume24
Issue number2
StatePublished - Jul 1 2008
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Neoplasms
Recurrence
Survival Rate
Renal Insufficiency
Thiotepa
Ureteroscopy
Peer Review
Mitomycin
Mycobacterium bovis
Conservative Treatment
MEDLINE
Gold
Disease Progression
Urinary Bladder
Therapeutics
Quality of Life
Databases
Morbidity
Kidney

Keywords

  • Carcinoma
  • Endoscopy
  • Transitional cell
  • Ureteral neoplasms
  • Ureteroscopy

ASJC Scopus subject areas

  • Urology

Cite this

Conservative management of upper tract transitional cell carcinoma. / Iwaszko, Markian R.; Krambeck, Amy.

In: Indian Journal of Urology, Vol. 24, No. 2, 01.07.2008, p. 159-163.

Research output: Contribution to journalReview article

@article{7d408a40f2424f9cab630d1e1bf662f5,
title = "Conservative management of upper tract transitional cell carcinoma",
abstract = "Aim: Our aim was to review the current literature describing the endoscopic management of upper tract transitional cell carcinoma (TCC). Materials and Methods: Review of published, peer-reviewed articles relating the primary ureteroscopic or percutaneous management of upper tract TCC was performed using the MEDLINE database. Results: Historically, the gold-standard management for upper tract TCC consists of nephroureterectomy with excision of a bladder cuff. The employment of endoscopic management with these neoplasms was initially instituted in individuals with imperative indications, including bilateral disease, solitary kidney, and/or renal insufficiency. For individuals treated with ureteroscopy, recurrence rates range from 30 to 71{\%} and cancer-specific survival rates from 50 to 93{\%}. Results are dependent primarily on tumor grade and stage. In individuals with low-stage, low-grade tumors treated percutaneously, recurrence rates, and cancer-specific survival rates are 18-33{\%} and 94-100{\%}, respectively. Adjuvant therapy has been employed with thiotepa, mitomycin, and BCG, but none have been able to demonstrate a statistically significant difference in recurrence or cancer-specific survival rates. Conclusions: Endoscopic management is a safe and effective treatment alternative to nephroureterectomy in the management of upper tract TCC. Survival outcomes are comparable, but renal preservation therapy offers the advantage of reduced morbidity, complications, and the potential for better quality of life. Recurrence and disease progression are not uncommon and underscore the need for strict tumor surveillance.",
keywords = "Carcinoma, Endoscopy, Transitional cell, Ureteral neoplasms, Ureteroscopy",
author = "Iwaszko, {Markian R.} and Amy Krambeck",
year = "2008",
month = "7",
day = "1",
language = "English (US)",
volume = "24",
pages = "159--163",
journal = "Indian Journal of Urology",
issn = "0970-1591",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - Conservative management of upper tract transitional cell carcinoma

AU - Iwaszko, Markian R.

AU - Krambeck, Amy

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Aim: Our aim was to review the current literature describing the endoscopic management of upper tract transitional cell carcinoma (TCC). Materials and Methods: Review of published, peer-reviewed articles relating the primary ureteroscopic or percutaneous management of upper tract TCC was performed using the MEDLINE database. Results: Historically, the gold-standard management for upper tract TCC consists of nephroureterectomy with excision of a bladder cuff. The employment of endoscopic management with these neoplasms was initially instituted in individuals with imperative indications, including bilateral disease, solitary kidney, and/or renal insufficiency. For individuals treated with ureteroscopy, recurrence rates range from 30 to 71% and cancer-specific survival rates from 50 to 93%. Results are dependent primarily on tumor grade and stage. In individuals with low-stage, low-grade tumors treated percutaneously, recurrence rates, and cancer-specific survival rates are 18-33% and 94-100%, respectively. Adjuvant therapy has been employed with thiotepa, mitomycin, and BCG, but none have been able to demonstrate a statistically significant difference in recurrence or cancer-specific survival rates. Conclusions: Endoscopic management is a safe and effective treatment alternative to nephroureterectomy in the management of upper tract TCC. Survival outcomes are comparable, but renal preservation therapy offers the advantage of reduced morbidity, complications, and the potential for better quality of life. Recurrence and disease progression are not uncommon and underscore the need for strict tumor surveillance.

AB - Aim: Our aim was to review the current literature describing the endoscopic management of upper tract transitional cell carcinoma (TCC). Materials and Methods: Review of published, peer-reviewed articles relating the primary ureteroscopic or percutaneous management of upper tract TCC was performed using the MEDLINE database. Results: Historically, the gold-standard management for upper tract TCC consists of nephroureterectomy with excision of a bladder cuff. The employment of endoscopic management with these neoplasms was initially instituted in individuals with imperative indications, including bilateral disease, solitary kidney, and/or renal insufficiency. For individuals treated with ureteroscopy, recurrence rates range from 30 to 71% and cancer-specific survival rates from 50 to 93%. Results are dependent primarily on tumor grade and stage. In individuals with low-stage, low-grade tumors treated percutaneously, recurrence rates, and cancer-specific survival rates are 18-33% and 94-100%, respectively. Adjuvant therapy has been employed with thiotepa, mitomycin, and BCG, but none have been able to demonstrate a statistically significant difference in recurrence or cancer-specific survival rates. Conclusions: Endoscopic management is a safe and effective treatment alternative to nephroureterectomy in the management of upper tract TCC. Survival outcomes are comparable, but renal preservation therapy offers the advantage of reduced morbidity, complications, and the potential for better quality of life. Recurrence and disease progression are not uncommon and underscore the need for strict tumor surveillance.

KW - Carcinoma

KW - Endoscopy

KW - Transitional cell

KW - Ureteral neoplasms

KW - Ureteroscopy

UR - http://www.scopus.com/inward/record.url?scp=43149111078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149111078&partnerID=8YFLogxK

M3 - Review article

C2 - 19468390

AN - SCOPUS:43149111078

VL - 24

SP - 159

EP - 163

JO - Indian Journal of Urology

JF - Indian Journal of Urology

SN - 0970-1591

IS - 2

ER -